ARS Pharma stockholders elect four Class II directors, ratify Ernst & Young as auditor

ARS Pharmaceuticals, Inc.

Elect directors Richard Lowenthal, Peter Kolchinsky, Brenton Saunders, Peter Thompson to 2028 term.
Lowenthal receives 64.9M votes for, 3.0M withheld; Kolchinsky 55.8M for, 12.1M withheld.
Saunders gets 56.2M for, 11.8M withheld; Thompson gets 61.8M for, 6.1M withheld.
Broker non-votes on director election: 9.6M shares for each nominee.
Auditor ratification passes with 77.3M for, 0.2M against; no broker non-votes.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.